Skip to main content

Pilot Study for New Chronic Pain Treatment Protocol with Nexstim NBT® System Starts in Helsinki University Hospital

Written by Customer Service on . Posted in Public Companies.

Company Announcement, Inside Information, Helsinki, 25 September 2020 at 9.50 am (EEST)Pilot Study for New Chronic Pain Treatment Protocol with Nexstim NBT® System Starts in Helsinki University HospitalNexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “Company”) announces that a pilot study on the use of accelerated iTBS protocol in treatment of therapy resistant, chronic neuropathic pain with Nexstim NBT® System is starting at Helsinki University Hospital.Accelerated iTBS means transcranial magnetic stimulation (TMS) therapy where stimulation is given several times a day during individual days. In conventional TMS therapy for pain, stimulation is given once a day during several weeks.In the Helsinki University Hospital pilot study, the effectiveness of the accelerated iTBS protocol will be tested in 5-10 patients. They are suffering from therapy resistant, chronic neuropathic pain and have not benefited from prior 10 Hz rTMS treatment targeted to the motor cortex.Their treatment will begin in the last quarter of this year and all the treatments are estimated to be completed in first half of 2021. The results of the study will be announced as soon as possible after their completion.Mikko Karvinen, CEO of Nexstim, commented: “Starting a pilot study using accelerated iTBS protocol treatment in therapy resistant chronic pain is one of our strategic goals for 2020. Helsinki University Hospital has successfully used Nexstim NBT® system with SmartFocus® TMS in pain therapy for a long time already – we are very delighted that they have now decided to conduct this pilot study.”
Further information is available on the website www.nexstim.com or by contacting:Mikko Karvinen, CEO
 +358 50 326 4101
mikko.karvinen@nexstim.com
Erik Penser Bank AB (Certified Adviser)                           
 +46 8 463 83 00
certifiedadviser@penser.se
About Nexstim PlcNexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.For more information please visit www.nexstim.comAttachmentNexstim_Company Announcement_Pilottitutkimus krooninen kipu_HYKS_FINAL_EN

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.